Posted by Michael Wonder on 09 Aug 2017
Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment
9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA.
The Institute for Clinical and Economic Review has posted a draft scoping document on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies.
The document will be open to public comment for three weeks until 29 August 2017. It will inform a report assessing the comparative clinical effectiveness and value of CAR-T therapies, which will serve as the basis of discussion during a March 2018 public meeting of the California Technology Assessment Forum.
